ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
65,405.88
-2.02%
S&P 500
5,425.38
-0.15%
Dow Jones
38,547.87
-0.26%
US Dollar vs Yen
157.2925
0.10%
Brent Oil
82.355
0.46%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Context Therapeutics Inc (CNTX)

  7. Context Therapeutics Inc (CNTX) ニュース

CNTX

Context Therapeutics (CNTX)

Context Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:CNTX
日付受信時刻ニュースソース見出しコード企業名
2024/06/1420 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTXContext Therapeutics Inc
2024/06/1420 : 34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
2024/06/0313 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CNTXContext Therapeutics Inc
2024/06/0105 : 06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CNTXContext Therapeutics Inc
2024/05/2505 : 15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CNTXContext Therapeutics Inc
2024/05/2420 : 31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CNTXContext Therapeutics Inc
2024/05/1705 : 01Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CNTXContext Therapeutics Inc
2024/05/1105 : 00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CNTXContext Therapeutics Inc
2024/05/0905 : 06GlobeNewswire Inc.Context Therapeutics Reports First Quarter 2024 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
2024/05/0905 : 03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTXContext Therapeutics Inc
2024/05/0220 : 31GlobeNewswire Inc.Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76NASDAQ:CNTXContext Therapeutics Inc
2024/05/0220 : 30GlobeNewswire Inc.Context Therapeutics Announces $100 Million Private PlacementNASDAQ:CNTXContext Therapeutics Inc
2024/04/0120 : 30GlobeNewswire Inc.Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive CancersNASDAQ:CNTXContext Therapeutics Inc
2024/03/2120 : 43GlobeNewswire Inc.Context Therapeutics Reports Full Year 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
2024/03/0621 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
2024/02/0806 : 24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CNTXContext Therapeutics Inc
2023/11/1006 : 15GlobeNewswire Inc.Context Therapeutics Reports Third Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
2023/11/1006 : 04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTXContext Therapeutics Inc
2023/10/3122 : 04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
2023/10/3122 : 00GlobeNewswire Inc.Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76NASDAQ:CNTXContext Therapeutics Inc
2023/09/2722 : 00GlobeNewswire Inc.Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:CNTXContext Therapeutics Inc
2023/08/1005 : 10GlobeNewswire Inc.Context Therapeutics Reports Second Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
2023/08/1005 : 04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTXContext Therapeutics Inc
2023/08/0721 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTXContext Therapeutics Inc
2023/08/0120 : 30GlobeNewswire Inc.Context Therapeutics to Participate in Two August 2023 Investor ConferencesNASDAQ:CNTXContext Therapeutics Inc
2023/06/2021 : 36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTXContext Therapeutics Inc
2023/06/0105 : 53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTXContext Therapeutics Inc
2023/05/1105 : 39GlobeNewswire Inc.Context Therapeutics Reports First Quarter 2023 Operating and Financial ResultsNASDAQ:CNTXContext Therapeutics Inc
2023/04/0320 : 30GlobeNewswire Inc.Context Therapeutics to Participate in Two April 2023 Investor ConferencesNASDAQ:CNTXContext Therapeutics Inc
2023/03/2805 : 04Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:CNTXContext Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CNTX

最近閲覧した銘柄

NYSE
NKE
Nike
USOTC
RHHBY
Roche (QX)
NYSE
CVX
Chevron
NASDAQ
GOOGL
Alphabet
COIN
ETHUSD
Ethereum
CCOM
US100
US Tech 100
AMEX
SPY
SPDR S&P 500
AMEX
XLF
Financial Select Sector
CCOM
SILVER
SILVER
NASDAQ
TSLA
Tesla
FX
USDGBP
US Dollar vs Sterling
NYSE
BAC
Bank of America
COIN
BTCUSD
Bitcoin
NASDAQ
AMZN
Amazon.com
NYSE
KO
Coca Cola
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有